Novartis gene therapy would be cost effective up to $900,000: U.S. group

The Boston-based Institute for Clinical and Economic Review (ICER) made the determination using a commonly cited cost-effectiveness threshold that values each "quality-adjusted life year" (QALY) gained at $100,000 to $150,000.If each QALY gained were assessed at $500,000, ICER found the gene therapy, Zolgensma, would be cost effective at just over $5 million.Novartis has said the price will be determined in negotiations with health plans, but it believes the gene therapy would be cost effective